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Abstract
Background Patient participation on both the individual and the
collective level attracts broad attention from policy makers and
researchers. Participation is expected to make decision making
more democratic and increase the quality of decisions, but empiri-
cal evidence for this remains wanting.
Objective To study why problems arise in participation practice
and to think critically about the consequence for future participa-
tion practices. We contribute to this discussion by looking at
patient participation in guideline development.
Methods Dutch guidelines (n = 62) were analysed using an
extended version of the AGREE instrument. In addition, semi-
structured interviews were conducted with actors involved in
guideline development (n = 25).
Results The guidelines analysed generally scored low on the item
of patient participation. The interviews provided us with important
information on why this is the case. Although some respondents
point out the added value of participation, many report on diﬃ-
culties in the participation practice. Patient experiences sit uncom-
fortably with the EBM structure of guideline development.
Moreover, patients who develop epistemic credibility needed to
participate in evidence-based guideline development lose credibility
as representatives for ‘true’ patients.
Discussion and conclusions We conclude that other options may
increase the quality of care for patients by paying attention to
their (individual) experiences. It will mean that patients are not
present at every decision-making table in health care, which may
produce a more elegant version of democratic patienthood; a ver-
sion that neither produces tokenistic practices of direct participa-
tion nor that denies patients the chance to contribute to matters
where this may be truly meaningful.
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Introduction
Climbing the token-participation ladder?
Patient participation in health-care decision
making attracts broad attention from both
researchers and policy makers. On the individ-
ual level the importance of patient-centred care
and tailor-made services is emphasized. For
this patients are asked to play an active role in
their care. Also on the collective level, partici-
pation is proposed, for instance in decision
making on government policy, quality projects
in health-care institutions, medical research
and guideline development.1 On both levels,
the arguments in favour of participation are
intrinsic as well as instrumental. Firstly, it is
argued that patient participation is important
for reasons of democratic decision making. In
addition to this intrinsic argument it is argued
that participation will lead to better quality
decisions.1–5 On the individual level this could
lead to tailor-made services. On the collective
level the experiential knowledge of patients is
considered an additional perspective to that of
other actors (such as policy makers, health-care
professionals and researchers). This knowledge
can be used to challenge epistemic assumptions
in medical research practices6–9 and improve
the patient centredness of health care in gen-
eral. Guideline development, the focus of this
article, is an important example where the par-
ticipation of patients is proposed and expected
to achieve this dual aim of improving the qual-
ity of guidelines and making the process more
democratic.10 Policy makers in an increasing
number of countries acknowledge that patients
should participate in guideline development.11
Moreover, one of the items of AGREE, the
widely used international evaluation instrument
for the development of medical guidelines, con-
siders whether patients have been involved in
the process.12
Although there are many studies emphasiz-
ing the importance of patient participation for
the above-mentioned reasons, there are also
studies that reﬂect on this issue in a more criti-
cal way. A critical assessment is made of both
the ideological basis and the way participation
works out in practice. Firstly, it is argued that
participation may result in shifting burdensome
responsibilities onto the shoulders of patients,
who in fact do not want this responsibility.13
Patients may not be able to carry this responsi-
bility which could lead to quality reduc-
tions.14,15 Secondly, it is argued that
participation does not deliver its intended
results in terms of better quality decision
making. It is hard to point out the inﬂuence of
patients when they do participate in collective
health-care decision making and contributing
proves a diﬃcult job for patient representa-
tives.3,16–18 Participation in practice can there-
fore often be described as tokenistic.19,20
Frequently, the fact that participation does
not result in the envisioned advantages leads to
the promissory conclusion that a bigger eﬀort
should be made to make these processes a suc-
cess. The ideological appeal seems to push the
discussion into this direction. Regularly refer-
ence is made to Arnsteins ladder of participa-
tion21; patients are not an equal partner yet
and therefore should climb this ladder.3,22–24 In
short, an important ideal is that more partici-
pation is better. However, the diﬃculties in
practice and critical views on participation
question whether this enthusiasm needs adjust-
ment.19,25 Current research into participation
in guideline development oﬀers important
insights into these practices, such as the per-
ceived goals behind participation, the knowl-
edge domains playing a role in development
processes and the methods which can be used
for participation.10,17,26–28 However, in light of
the debate described above it is important to
gain a deeper understanding about these partic-
ipation practices. This study aims to increase
our knowledge about participation in guideline
development and why problems arise. Further-
more, it aims to oﬀer a reﬂection on the conse-
quences of these results for future participation
practices. We will do so by answering the fol-
lowing research question: Are patients involved
in the development in Dutch guidelines, what are
the experiences with this and how can participa-
tion practices be improved?
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Methods
A mixed-method study of participation in
guidelines
This study is based on broader studies into
guideline development and patient participa-
tion in health care.18, 29 Both quantitative and
qualitative methods were used to study the
subject of patient participation in guideline
development. We analysed 62 Dutch guidelines
for the ‘top 25 conditions’ developed by the
Dutch Council for Quality of Healthcare.30 We
scored these guidelines using an extended ver-
sion of the Appraisal of Guidelines Research
and Evaluation (AGREE I12) instrument. This
instrument includes an item on patient partici-
pation (item 5): “The patients’ views and pref-
erences have been sought”. In our study we
extended this item with three items. Firstly,
“Patient participation was used in the develop-
ment process”. Because patient participation
does not equal inﬂuence we secondly scored
the guidelines on the item: “The input of
patients can be identiﬁed in the guideline”.
Thirdly, the importance of patient participation
is not only emphasized in collective health-care
decision making but also on the individual
patient level. Guidelines could help participa-
tion on this level by providing patients with
information about their condition and treat-
ment possibilities. Therefore, we also scored
the guideline using the item: “Attention is paid
to the accessibility of the guideline for
patients”. In line with the AGREE instrument,
a four-point likert scale was used, ranging from
1 (strongly disagree) to 4 (strongly agree). In
addition, we included explanatory comments
about the scores attributed to a certain item.
The scoring of the guidelines on the subject of
patient participation was done by two research-
ers (one of the authors HvdB and another
researcher involved in the project) with exper-
tise on the topic of patient participation. To
ensure inter-rater agreement, a checklist on the
subject of patient participation and informa-
tion (e.g. participation methods used, who par-
ticipates, ways of reporting on patient input in
the guideline) was developed to make the scor-
ing of the guidelines more systematic. Next, to
scoring the items, the researchers took notes
on these issues (e.g. which methods were used
etc.). After scoring the items the researchers
discussed their scoring method and checked for
large diﬀerences (e.g. more than one point) to
see whether a consensus agreement needed to
be reached based on these notes. Therefore,
rather than merely reporting inter-rater reliabil-
ity scores, we chose a more substantive
approach to diﬀerences in scoring the guide-
lines.
In addition to the analysis of the guidelines,
semi-structured interviews were conducted with
actors involved in guideline development. We
selected two types of respondents; some of
them being directly involved in the develop-
ment of the guidelines analysed, whereas others
were selected for their involvement in guideline
development in the Netherlands more gener-
ally. We felt this was important to gain insight
into patient participation by investigating
developments and experiences over time, as
well as by studying in detail how patient par-
ticipation worked out in practice.
Respondents were selected based on their
expertise on guideline development and their
participation in guideline development pro-
cesses [both professionals and people responsi-
ble for the organization of guideline
development (n = 15)]. A ﬁrst selection was
made based on our knowledge of the ﬁeld.
Additional respondents were identiﬁed using
the snowballing technique. In addition, inter-
views with representatives of patient organiza-
tions (n = 10) were conducted to learn more
about their views on and experiences with par-
ticipation, including in guideline development.
Interviews were semi-structured based on a
topic list that focused on empirical experiences
and examples. Topics discussed included: ideas
on the importance of patient participation,
experiences with participation and, based on
those, ideas about the future of participation.
All the interviews were recorded and tran-
scribed verbatim and analysed by incremental
coding. Quotations used have been slightly
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modiﬁed only to ensure anonymity and
legibility.
Results
The pitfalls and promises of participation
We will ﬁrst discuss whether patients are given
the opportunity to participate in guideline
development. Thereafter, we will focus on how
they can participate and how the practice of
participation relates to the goals behind partici-
pation. Thirdly, we will discuss alternative and
potentially more productive possibilities to
reach these goals.
Do patients participate?
It is quite noticeable that in general the guide-
lines we analysed scored fairly low on the
subject of patient participation and informa-
tion. Figure 1 gives an overview of the guide-
lines analysed. They are categorized according
to the ‘top 25 conditions’ developed by the
Dutch Council for Quality of Healthcare
(there are several guidelines available for most
conditions). We should be aware that this low
score does not automatically mean that there
was no patient involvement. It could also be
that patients were involved but this was not
explicitly mentioned in the guideline. How-
ever, on the basis of these results it seems
plausible that patient participation in the
development process is not common practice.
There are exceptions; some multidisciplinary
guidelines score high on this item. The most
important ones are the multidisciplinary men-
tal health guidelines on depression and anxiety
disorders and the multidisciplinary guideline
on chronic heart failure. Interviews with peo-
ple involved in the development of these
guidelines made it evident that explicit atten-
tion was paid to involving patients in these
cases.
A low score on patient involvement does not
only mean that developers had not thought of
asking patients to participate or were sceptical
about involvement of patients per se: some-
times guideline developers make the deliberate
choice not to involve patients because they feel
that patient contributions will be too general
for the question the speciﬁc guideline is trying
to answer:
We have deliberately chosen, that has been a big
discussion, not to involve patients that much.
Because then you will get all these chapters on
‘the patient needs to be informed properly’, ‘the
patient needs to be supported properly’, ‘the
patient needs this’ and ‘the patient needs that’,
and that is of course the same for every oncology
patient. So we said we are not going to invest
time and money in that [within a speciﬁc guide-
line] (chairperson guideline).
Respondents from patient organizations do
not always see the added value of participation
either, as according to them professionals have
the knowledge needed to develop a good guide-
line:
No [we do not have to participate] these are peo-
ple who know better, even than me (representa-
tive patient organization).
Other respondents were part of guideline
development processes where the choice was
made to involve patients. This choice some-
times results from participation being a crite-
rion to get development grants. At other times
guideline developers genuinely feel that partici-
pation is important. Several respondents point
out the added value of participation. Patients
can bring additional subjects to the table, for
instance, on how they experience care at a cer-
tain point in the care trajectory:
Waiting times, professionals see it just as waiting
times, but for patients it does not feel like wait-
ing times since a lot has to happen during that
period. So the time between diagnosis and treat-
ment is not ‘wait and see’ for them although pro-
fessionals do experience it like that. I found that
one of the most extraordinary moments, when I
thought: ‘yes, patients do need to be present in
the development groups’ (guideline coordinator).
In many of the debates about participation,
the contribution of patients is mainly perceived
as relating to more experience-based aspects of
care.31 It can also be the case, however, that
the knowledge of patients is about aspects of
clinical questions that are not well covered in
© 2013 John Wiley & Sons Ltd
Health Expectations, 18, pp.942–955
Study of patient participation in guideline development, H M van de Bovenkamp and T Zuiderent-Jerak 945
studies. In the case of the development of a
guideline for Parkinson’s disease, the assump-
tion that generic prescribing would be prefera-
ble as the prescribed medication is ‘the same’
was challenged by patients during the analysis
of clinical questions:
Figure 1 Scoring of guidelines for ‘top 25 conditions’ on patient participation and information. The scores are the sum of the
scores on the questions relating to patient participation and information (a score of 4 (strongly agree) on all questions
would lead to a 100% score in the table).
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Then it turns out that substance A has three gen-
eric producers, but they [pharmacists] have to
adhere to certain margins within which they have
to make the drug. These margins are rather
broadly deﬁned; it has to contain an amount of
active substance that varies between 80 and
100% of the intended quantity. So there’s varia-
tion. Well, that’s all well and good once medica-
tion regimens are well attuned to a certain
variation, except when 3 months later the phar-
macists found another supplier who oﬀers sub-
stance A for even less. Then you switch to A1,
which can mean another amount of active sub-
stance (clinical guideline developer).
Although these margins within generics are
rarely speciﬁed in clinical studies, patients
were highly able to stress the importance of
deviating from generic prescribing for this spe-
ciﬁc category of drugs for which getting
patients properly attuned is such a tricky busi-
ness. This was included as a recommendation
within the guideline, and some insurers now
indeed try to stop the preference policy for
Parkinson medication. Patients thereby at
times turn out to be critically important for
getting the clinical recommendations right,
which is in line with previous research.6–9
Moreover, this problematizes the ideas of the
oncology guideline chairperson, who indicated
that patient participation merely leads to com-
ments about how patients are informed and
addressed.
Besides knowledge about the eﬀects of medi-
cation, patients of course are also able to pro-
vide more experience-based information about
living with a certain condition in relation to
guideline recommendations:
For instance in the case of ADHD there was
something about medication. Professionals focus
very much on compliance (…) the parent in the
development group however (…) said yes but my
kid likes it a lot, when he has a football match,
to take the pill after the game instead of before
the game because [that way] he will have more
fun. And I think things like that were taken up
[in the guideline] that you should always check
with the patient (advisor guidelines mental
healthcare).
In some cases patient organizations initiate
and organize guideline development. The
Dutch association of muscular diseases is an
example of this.
We take the initiative, we apply for grants, we
also get grants for [guideline development] and
together with the CBO [organization which sup-
ports guideline development] and with speciﬁc
specialist groups we make guidelines (representa-
tive patient organization).
Patient participation thereby seems to cover
a wide range of activities, spanning from
patient-initiated guidelines, via articulating
clinical aspects that are overlooked in studies,
to providing experience-based expertise on liv-
ing with a certain condition.
Diﬃculties
Our AGREE-based analysis and interviews
show that there are concrete examples where
indeed patients have participated and they
could contribute to the guideline development
process. However, this is not always the case.
Respondents also point out that there are
many diﬃculties with participation in practice.
For some, this results in expressing their feel-
ings against certain forms of participation,
such as patient involvement in the development
groups.
I am against it. I am against it. You can have a
committee on the side, it is important to keep a
feeling, you need to know the preferences, but if
they really participate in meetings almost always
aspects concerning certain interests will get the
upper hand over scientiﬁc aspects, then it
becomes a less interesting discussion for the sci-
entists (project leader guideline).
This respondent points out that according to
him patient representatives bring interests to
the table which should not be part of the dis-
cussions in the working group meetings. This
points to a diﬃculty with articulating experi-
ence-based expertise in the setting of evidence-
based guideline development: where interests
are intricately tied to conﬂict of interest when
discussing scientiﬁc literature. This also makes
patient experiences – that are inherently embod-
ied and ‘interested’ – problematic in the episte-
mic setting of a guideline development group.
Although not many respondents speak out
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against participation this strongly, many do
report diﬃculties with participation in practice.
For instance, the organization that develops
multidisciplinary guidelines on mental health
care, which scored high in our guideline analy-
sis, had put a layered participation structure in
place. This structure included a special client
committee evaluating the process, participation
in development groups, sometimes also in addi-
tional focus groups and the possibility to com-
ment on concept versions of the guideline. Still
also in these cases important diﬃculties arose:
Everybody has the right intentions, everybody
understands the importance and still it is really
diﬃcult (advisor guidelines mental healthcare).
We feel that it is important to learn more
about why participation in practice is so diﬃ-
cult and why guidelines generally score low on
this subject. Detailed empirical studies of
patient involvement tend to show highly inter-
esting examples of successful and often patient-
initiated participation.6,8 However, the main
strength of such cases may lie in the fact that
they point to the possibilities of speciﬁc forms
of participation, rather than them being indica-
tive of participation in very diﬀerent settings.
Analysing a wider range of participation prac-
tices in depth could oﬀer us ways to critically
assess whether the low scores we encountered
may point to other dynamics than the one in
the oft-cited cases. And whether these low
scores need to be considered as problematic in
the ﬁrst place. That this may not quite be the
case is shown by the guideline on suicide
(Suicidality from beginning to end), which scored
low in our quantitative analysis, as patients had
not been involved in the development process,
but which received an award from a patient
organization for its patient centredness.
How patients participate: tensions between
EBM and experiential knowledge
Why participation is diﬃcult in practice seems
very much to be a result of the way guideline
development processes are organized. Patients
do not easily ﬁt into this decision making
structure.
The guidelines mentioning participation in
the development process show that several par-
ticipation methods were used (sometimes multi-
ple methods were used in the development
process of one guideline): participation in the
guideline development group (n = 16), focus
groups (n = 8), commenting on concept ver-
sions of guidelines (n = 12), literature reviews
into patient preferences (n = 4), surveys (n = 1)
and a patient participation committee (n = 3).
Participation in the guideline development
group was the method used most, despite the
fact that this method was consistently
described during interviews as causing many
problems.
Above we have highlighted some examples
of patients contributing to the process and
sometimes the input of patients could be found
in the guidelines we analysed, for instance,
some have a separate chapter on this at the
end of the guideline. However, our quantitative
analysis also shows that patients participating
in the development process often did not mean
that their input could be identiﬁed in the guide-
line. It would of course be possible that their
input was incorporated without speciﬁc atten-
tion to the fact that it concerned patient input.
Our interviews, however, show that in at least
some instances, it was challenging to explicate
what patients contribute in the guideline. Con-
temporary guideline development in the Neth-
erlands is, just like in many other countries,
based on Evidence-Based Medicine (EBM)
principles. This means that the attempt is made
to make recommendations on the best avail-
able evidence reported in the scientiﬁc litera-
ture. There is a substantial debate about
whether this strong focus on scientiﬁc evidence
may be problematic in its own right.2,32–36
Some authors claim that scientiﬁc evidence and
experience-based knowledge are truly diﬀerent
in kind, and therefore argue for an equal status
of diﬀerent types of knowledge in clinical
guideline development.37 This would, however,
precisely lead to the kind of compartmentaliza-
tion of knowledge domains that would make it
even harder for patients to claim expertise on
matters of clinical evidence and practice which,
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as we showed above, could have serious down-
sides. Here, we therefore focus on how this
organization of formalizing knowledge inﬂu-
ences patient participation practices.
Firstly, the focus on scientiﬁc evidence as a
privileged source of knowledge to base recom-
mendations on means that many resources of
guideline development groups, both in terms of
time and funds, are spent on searching, weigh-
ing and discussing the literature, which is a dif-
ﬁcult task for patient representatives who are
asked to participate in such a group.
I think when it concerns the development of a
guideline, by that I mean weighing the evidence
(…) you really need an academic education for
that (guideline team member).
The strong focus on EBM and the system
used to evaluate the scientiﬁc studies and cate-
gorize them in terms of the strength of the evi-
dence does not only make discussions diﬃcult
to follow for patients, but it also makes it hard
to give the experiential knowledge of patients a
place in the guideline as it does not ﬁt this cat-
egorization structure.
Oh right then they wanted mindfulness for exam-
ple, and we really thought that was taking things
too far because we felt there is just no evidence
for that, so we don’t want that (chairperson
guideline).
Moreover, these diﬀerent types of knowledge
can lead to clashes in the development group,
which happened in the case of the guideline on
Lyme disease:
There the experts by experience and the profes-
sionals were at opposite ends. The professionals
used the evidence-based literature, in other words
simply put, 2 weeks of antibiotics and then the
disease is cured. The patients said: “No you can
experience complaints years after that (…) so
you have to take antibiotics much longer, that is
our experience”. And that is of course a problem
you are going to get when you involve too many
experts by experience (chairperson guideline).
Patients tap from another knowledge base,
which by no means is conﬁned to ‘living with
illness’ but is directly tied to the making of evi-
dence claims. It proves particularly diﬃcult to
introduce clinical patient knowledge within
EBM guideline development, as evidence in
such settings is carefully disentangled from per-
sons. The embodied experience of patients puts
them in a dependent position. Professionals,
equipped with evidence weighing procedures,
have much of a say about when knowledge of
patients is allowed to enter the scene.
It was a professor who felt like: “Listen I am a
professor on this issue, so don’t tell me what
works and what does not work”. And he had a
point because he knew the literature very well.
And he really did not like that his conclusions
were contested by someone who did not do a
PhD, or was not a professor (advisor guidelines
mental healthcare).
This situation, where patient participants
have diﬃculty being heard in the guideline
development group and the dependent position
they ﬁnd themselves in, causes some patient
representatives to question whether it is wise to
participate in such a group.
If you are just one expert by experience in such a
guideline group than you can say something a
hundred times but is does not get acknowledged
(…) and then a stamp is put on it: patient
approved. So the question is whether it is wise to
participate in such a guideline committee (repre-
sentative patient organization).
Others try to conform to the system, and
argue that as a patient representative you need
to develop certain skills; you need a combina-
tion of being an expert by experience and hav-
ing a thorough understanding of the literature.
Therefore, not just any patient can participate
in guideline development. Some train them-
selves for the task.
Because it happened that you said something
and then it did not come across since it was just
an opinion. But now I try to ﬁnd as much litera-
ture as possible and I will also attend a course to
be able to search Pubmed in detail, that you can
say this is what we want and this is written about
that (representative patient organization).
However, this professionalization of patient
representatives can be considered a tricky strat-
egy. For one, respondents report on instances
where patient representatives did try to back
up their story with research, but which went
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against studies brought in by other professional
group members. In one case, this led to heated
debate, frustration and in the end caused the
patient organization involved not to endorse
the guideline. This shows that even when con-
forming to the requirement of being a kind of
‘double-knowledge-expert’, knowledge brought
in by patients is still vulnerable and easily dis-
carded. Secondly, conforming to the dominant
discourse and working methods causes patient
representatives to professionalize in scientiﬁc
terms, which at times leads to other members
challenging whether such representatives are
still in the best position to bring in the experi-
ential knowledge they were asked to contrib-
ute. As a consequence, guideline developers
indicate that they not only listen to representa-
tives of patient organizations but also ask
patients who are not part of such an organiza-
tion for their opinion.
On the one hand you see a knowledge gap with
patients, that it is very complicated (…) on the
other hand we felt that it was becoming a bit too
professional (…), I did not want just patients
from the patient organization, but also ‘patients
in the wild’ so to speak (…) we wanted an analy-
sis of diﬃculties and not the position of the
patient organization (project leader guideline).
Others claim that health-care professionals
who come into regular contact with many
patients have a better idea about what patients
want.
Through all kinds of channels in GP care, the
contacts between people making the guideline
and patients are very strong in practice, so, to
tell you the truth, we know what patients want.
And the selected sample [of patients] that partici-
pates in the group, it says the wrong things since
it is not representative (project leader guideline).
The professionalization of patients that is
needed for them to gain epistemic credibility in
guideline development groups, ironically pro-
duces doubts about their ability to represent
‘true’ patients ‘in the wild’. With professionals
having access to their own patients as well,
they start to look for more ‘direct’ patient
experiences, which they in turn claim to bring
into the guideline development meetings. In
this sense participation turns into a struggle
over whether professionalized patients or car-
ing professionals are best positioned to repre-
sent ‘the’ patient. This also shows that the
hopeful suggestions that patient participation
will improve by having better trained patients
is a strategy that may in fact weaken the posi-
tion of participating patients.
Reconﬁguring the tension: other forms of
participation and a focus on individual patients
Within the polarized scholarly debate on
patient participation, the results discussed so
far could be used to plead for the improvement
of the process of participation. In this view,
intensifying participation in guideline develop-
ment groups could overcome guideline develop-
ers’ unwillingness to divest from their
privileged epistemic hierarchy. However, our
results also show that these diﬃculties seem to
be an inherent part of the epistemic setting
patients are asked to participate in. They could
therefore also be used to plead against patient
participation in guideline development as it
does not deliver the promised results in prac-
tice. We feel that our ﬁndings also facilitate
moving beyond this dichotomy: our study
shows more fruitful ways to think about the
subject which recognize the inherent diﬃculties
as well as the contribution patients can make.
Firstly, it seems important to think critically
about when to involve patients and when not
to involve them in the development process
and how, if their knowledge is to stand a
chance in guideline development practices. This
means that patients do not necessarily have to
be part of the development group, but other
methods can be sought to involve them at par-
ticular points in the development process.
In general I think the moments you really need
them, then it is useful. But often patients are
dragged in because they have to be present, and
then they become kind of token-patients. Then I
think well that is a waste of time, also for the
patient (chairperson guideline).
The muscular disease association is of the
same opinion. It is an example of a patient
organization playing an important role in the
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development process; it initiated guideline
development and coordinated the process.
However, successful participation does not
mean that patients have to be present at every
decision-making moment.
Patient participation for me does not imply that
they have to sit at every table; the point is to
involve them in the trajectory at the right time to
get the information from patients that is relevant
(representative patient organization).
Deciding on the key questions that are at the
heart of the guideline and the key issues the
guideline should take into account seems an
important moment for patients to be involved.
This is also a phase where guideline developers
are critically aware that they should not phrase
the issue in the light of the available evidence,
but in line with the problems experienced in
practice. This seriously improves the chances
for participation turning into a productive
interaction.
If you don’t ask the right questions you will not
get the right answers. Eventually the focus
groups, including the focus group with patients,
were very helpful in determining the questions
(guideline team member).
We can conclude from this that the discus-
sion should move away from the participation
ladder, with the ideological connotation that
more intensive participation is better. In these
terms participation in a guideline development
group would be preferred over a focus group
with patients whereas in practice this does not
reach the goals of participation and causes
many problems. The discussion on patient par-
ticipation in guideline development as such,
therefore needs to shift to a focus on the
involvement of patients at certain stages of
guideline development, such as the stage of
deﬁning the starting questions, and for speciﬁc
recommendations within a guideline that
patients feel they can substantially contribute
towards.
A second way to broaden the debate is to
see guidelines as a means to make health care
more patient centred at the individual level.
Patient participation is often proclaimed to be
a means to make guidelines better by using
patient experiences, which should result in bet-
ter quality care for individual patients. It is
important to note that also the respondents
who quite bluntly state that participation is not
a good idea are not against the idea of patient-
centred care. Rather, their experiences cause
them to be critical to patient participation in
development groups as a means to accomplish
this. What these respondents emphasize is the
importance of providing care that ﬁts individ-
ual patient preferences.
People are diﬀerent, the patient does not exist,
just like the doctor does not exist. The challenge
is to make that visible at moments that choice
can really be considered important. Then you
can make that explicit [in the guideline] (guide-
line development expert).
It is therefore important to pay attention to
this fact when searching for scientiﬁc literature,
in discussing this literature, when formulating
the recommendations and developing patient
versions of the guideline. Uncertainty about
possible recommendations can thereby be turned
into a resource for shared decision making,
rather than into a problem for guideline
developers (Van Loon and Bal, submitted).
The importance of professionals taking into
account the preferences and experiences of
individual patients and the importance of
communication is also shown in the examples
of patients making a diﬀerence in the guideline
development process.
Discussion
From representation to knowledge articulation
This study focused on patient participation in
guideline development in the Netherlands. We
studied a sample of the guidelines available in
the Dutch context and interviewed respondents
who participated in a number of these. A more
extensive study would have provided us with a
more comprehensive picture of the situation in
the Netherlands. However, our data presented
us with some clear ﬁndings concerning the topic
of patient participation from which lessons can
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be drawn for participation practices and which
can serve as input for future research and prac-
tice. Moreover, some important ﬁndings we
present in our study are supported by the inter-
national literature (see below), which empha-
sizes the relevance of our ﬁndings for an
international audience. Another limitation of
this study is that it still made use of the
AGREE I instrument, as AGREE II was not
available at the time. This means the scores are
somewhat less speciﬁc, as the change from the
4- to the 7-point likert scale was not included.
The goals behind patient participation in
health-care decision making can be categorized
as democratization and increased quality of
decisions. Our study shows that these goals are
rarely accomplished in case of participation in
guideline development practices. Patients expe-
rience diﬃculties in inﬂuencing the process,
which means the goal of better quality deci-
sions, despite promising exceptions, is often
not reached. Moreover, their dependent posi-
tion and the fact that their professionalization
sparks representativeness questions among
guideline developers if patients start educating
themselves scientiﬁcally, points to problems of
conceiving of participation as ‘more demo-
cratic’. The content expertise that is required to
participate, easily leads to challenged legiti-
macy in that very participation.
Idealized models of involvement are prob-
lematic for all parties involved.38 We argue
that it is important to disentangle the ideologi-
cal appeal of participation and the expectations
for increased quality decision making. This
way alternative routes to successful participa-
tion can be sought. When the increased quality
of decisions is not found in practice, the ideo-
logical appeal seems to force the discussion
into one direction: participation eﬀorts should
be improved and by that it is meant they
should be increased. A review on the subject of
patient participation in guideline development
shows that this tendency exists in the literature
on guideline development.10 Talking in terms
of the participation ladder aggravates this ten-
dency. Moreover, the ‘more is better’ way of
thinking is also incorporated into scoring lists
such as AGREE which, in spite of warnings to
the contrary in the introduction to the instru-
ment, suggest that a higher score (more partici-
pation possibilities) will result in a better
guideline, as the score of the guideline is easily
misread as an indication of the quality thereof.
Our results, however, stress that this need not
be the case. Examples are shown of guidelines
with low scores that are highly valued from a
patient-centredness perspective. In contrast,
respondents involved in the development of
guidelines that reach high scores, report on
important participation problems. These diﬃ-
culties seem inherent to the way patient partici-
pation is presently positioned within guideline
development, which precludes making the best
use of the knowledge patients bring to the
table. Based on our results the argument can
be made that we should resist the reﬂex of
arguing for more intensive participation but
explore other options instead.
Reviews of the international literature show
that the diﬃculties identiﬁed in this article are
not typical for the Dutch case.10,39 They seem
inherent to the forum oﬀered for participation
and ingrained in the participation practice.
Within this practice of evidence-based guideline
development combined with the ideal of full
guideline development group membership by
patients, patient representatives are trying to
professionalize which may include them in the
discussion (although not necessarily), but
makes them lose their credibility as representa-
tives of ‘true’ patients within the group. We
therefore conclude that the recommendation
that patients should be trained and profession-
alized to solve problems in participation prac-
tices is not a fruitful solution, as it could in
fact decrease epistemic legitimacy. Ironically,
such participation, even when less successful in
articulating patient knowledge, does pose the
risk that the guideline is considered ‘patient-
centred’, as patient representatives had the
opportunity to participate in the development
process. As some respondents pointed out, this
may then even decrease the chances of a guide-
line contributing to patient-centred care at the
individual level.10
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The above points to the importance of
exploring other routes to improve participation
practice, which we can contribute to based on
our results. Making critical decisions about
when and how participation in guideline devel-
opment is important and likely to be produc-
tive and – just as importantly – when it is not
is crucial. Our ﬁndings suggest that deciding
on the key questions the guideline is supposed
to address is one such moment. This can be
done for instance through the use of focus
groups. Such methods allow for participation
in a forum, where the epistemic setting that is
so problematic for patient knowledge, is less of
a given and patient experiences are more likely
to gain legitimacy.40 The importance of the
contribution to deciding on key questions has
also been reported in the literature.41 Further-
more, attention can be paid in the development
process to the importance of individual patient
preferences and which moments are crucial to
discuss diﬀerent treatment options.10 This way
guidelines can indeed be used as a means to
facilitate patient choice.42 Including sections on
patient–professional communication, the
importance of which for patients is stressed
both in our ﬁndings and in the literature,10,41,43
needs to be treated with some caution though,
as this is easily perceived by other group
members as non-speciﬁc to the guideline at
hand and re-enact stereotypical ‘patient
complaints’.
To conclude, our results indicate that there
are options that could be more promising to
improve the prospects of participation. It will
mean that patients are not present at every
decision-making table in health care, which
may even be a more elegant version of demo-
cratic patienthood. A version that neither
produces tokenistic practices of direct partici-
pation nor that denies patients the chance to
contribute to matters where this may be truly
meaningful. These recommendations also have
consequences for evaluation instruments such
as AGREE, which should appreciate such
more targeted participation possibilities. As
long as AGREE merely makes visible the score
on whether patients participated, it does not
suﬃce to state in the user manual for the
instrument that:
“Although the domain scores are useful for com-
paring guidelines and will inform whether a
guideline should be recommended for use, the
Consortium has not set minimum domain scores
or patterns of scores across domains to diﬀerenti-
ate between high quality and poor quality guide-
lines. These decisions should be made by the user
and guided by the context in which AGREE II is
being used.”44*
Using AGREE for the assessment of individ-
ual guidelines far too easily leads to mistaken
conclusions about the diﬀerence between a
score on patient participation and the value of
it. We see this as one of the main limitations
of instruments like AGREE for the appraisal
of conceptually contentious issues like patient
participation.
On the one hand, we hereby hope to point
out the importance of the emerging literature
of longitudinal and in-depth ethnographic stud-
ies of interesting participation practices,6,8 as
these are highly relevant for coming to in-
depth understanding of epistemic practices in
those speciﬁc instances. On the other hand, our
study also shows that a more general study of
successful and problematic practices of patient
participation by means of mixed methods like
using the AGREE instrument for appraising
trends in large sets of guidelines with qualita-
tive in-depth analysis, may be equally impor-
tant to make sure the persistent limitations of
participation are investigated and addressed.
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